AstraZeneca PLC announced Monday that it has received approval from the U.S. Food and Drug Administration (FDA) for a new form of its popular Seroquel schizophrenia treatment, making it the first medicine to treat both the manic and depressive sides of bipolar disorder.

Seroquel, launched in 1997, is one of AstraZeneca's top-selling drugs, with total sales of $2.8 billion last year. The drug is already used to treat acute manic episodes associated with bipolar disorder and schizophrenia, but the FDA approval adds the treatment of patients with depressive episodes

Some drugs used to treat patients with Alzheimer's disease do little to calm some of the malady's more dramatic symptoms, and may even pose a risk of serious side effects, according to a study due out, today.

The study, published in The New England Journal of Medicine, finds that some popular medications prescribed to ease agitation and aggression were no more effective than placebos for most Alzheimer's patients. The study goes on to say that the drugs may actually lead to confusion, sleepiness and Parkinson's disease-like symptoms in some patients

A comparison of five schizophrenia drugs finds most newer treatments fare no better than an older generic drug, despite higher costs, according to a study released Monday.

The only exception is Eli Lilly and Co.'s Zyprexa, which may be better than the other medicines. Apart from being the most expensive drug, the study found Zyprexa users experienced dramatic weight gain and developed a higher risk of diabetes